Yecla, Arman D.
HRN: 22-35-65 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/26/2022
CEFTRIAXONE 1G (VIAL)
12/26/2022
01/02/2023
IV
1g
Q12
Fracture
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes